摘要
[目的]探讨化疗联合CIK细胞回输治疗转移性肾癌的疗效。[方法]40例mRCC患者,采用GEM+5-Fu化疗,化疗结束后分次回输CIK细胞,同时给予IL-2和IFN-α。所有患者均接受至少2个周期治疗。[结果]40例患者中4例PR(10.0%),22例SD(55.0%),14例PD(35.0%),无进展生存时间(PFS)为87d。Ⅲ～Ⅳ度毒副反应占27.5%。[结论]化疗联合自体CIK细胞回输对mRCC患者有效,并延长PFS,是一种可接受的治疗模式。
[Purpose] To investigate the clinical effect of chemotherapy combined with autologous cytokine-induced killer （CIK） cells transfusion in the treatment for metastatic renal cell carcinoma （mRCC）. [Methods] Fifty-six cases with mRCC were enrolled and underwent chemotherapy with 5-Fu and Gemcitabine followed by transfusion of CIK, IL-2 and IFN-α treatment. All patients received at least two cycles therapy. [ Results ] Of the 40 cases, 4 were PR （10.0%）; 22 （55.0%）, SD; 14 （35.0%）, PD. Progression free survival （PFS） was 87d; Ⅲ-Ⅳdegree toxicity accounted for 27.5%. [Conclusions] Patients with mRCC can benefit from the combination of chemotherapy and autologous CIK transfusion, The treatment can prolong the peroid of PFS, and is a acceptable treatment modality.
出处
《肿瘤学杂志》
CAS
2008年第5期362-365,共4页
Journal of Chinese Oncology
